Our gynecologic oncology program is recognized as one of the world's finest and is ranked #2 in the 2017 U.S. News & World Report.

We provide patients with:

- the latest minimally invasive, image-guided techniques for diagnosis and treatment of cervical, uterine, and ovarian cancers, and gestational trophoblastic disease
- access to innovative clinical trials of chemotherapy, surgical techniques, and advanced technologies not available at other hospitals
- an individualized treatment plan

LOCATIONS

Many of our specialists are centrally located at our Manhattan location. We also have regional outpatient locations in:

- MSK Basking Ridge, New Jersey
- MSK Monmouth, New Jersey
- MSK Commack, Long Island
- MSK Rockville Centre, Long Island
- MSK Westchester, West Harrison

Our Team Leaders

Nadeem R. Abu-Rustum, MD, FACOG, FACS
Chief, Gynecology Service; Vice Chair for Technology Development, Department of Surgery

Carol Aghajanian, MD
Chief, Gynecologic Medical Oncology Service

Evis Sala, MD, PhD
Chief, Body Imaging Service

Kaled Alektiar, MD, FASTRO
Radiation Oncology Service

Robert Soslow, MD
Director, Gynecologic Pathology

REFER A PATIENT

Contact our Physician Access Service directly at 800-525-2225

MSK has insurance contracts with most major health plans in the New York tristate area.

Sign up for OncoNotes, MSK’s clinical updates newsletter.

Go to MSKCC.org, click on the For Health Professionals section, and choose “Sign up for our e-newsletter.”
Leadership

- Our team developed the sentinel lymph node mapping algorithm for endometrial and cervical cancer that is now a standard of care in the National Comprehensive Cancer Network guidelines.
- Our researchers are investigating emerging immunotherapy approaches — immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cell therapy — for solid tumors.
- We are studying the use of secondary cytoreduction with and without hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer.
- We routinely utilize MSK-IMPACT™ (Integrated Mutation Profiling of Actionable Cancer Targets) to test for mutations in both rare and common cancers. This provides our oncologists with unparalleled assessment of the tumor molecular profile.

Advanced Technologies

- We use the latest laparoscopic and robotic surgical techniques resulting in greater precision, fewer complications, decreased postoperative pain, shorter hospital stays, and faster recovery compared with open surgery.
- We pioneered several approaches using infrared technology advances in visualizing lymphatics during uterine and cervical cancer surgery and continue to investigate the role of [18F]-fluorodeoxyglucose (FDG) lymphography and nanoprobes in gynecologic cancer surgery.
- Our 24/7 pathology lab processes digitized images of tissue samples very quickly, including during surgery, to help patients avoid unnecessary procedures.

Expertise

- We perform more than 450 operations per year for new endometrial cancer.
- We are the first hospital in the United States to create a dedicated advanced ovarian cancer team.
- We offer the largest fertility-preserving surgery program in the United States using the radical trachelectomy procedure—an alternative to radical hysterectomy—in eligible cervical cancer patients.
- The majority of younger women who undergo trachelectomy can conceive naturally and deliver full-term babies.
- We have one of the largest uterine sarcoma programs in the world, with extensive expertise in surgery and chemotherapy for complex advanced and recurrent disease.

WHY CHOOSE MSK FOR GYNECOLOGIC CANCER CARE?

By the Numbers

- 2,300 gynecologic cancer operations per year
- 54 gynecologic cancer specialists
- 18 gynecologic medical oncology specialists
- 8 locations
- 13 gynecologic surgeons